基因多态性与各种肿瘤的关系

2003 年

Kripp l等[ 1 ]报道VEGF 936 C等位基因携带者患乳

腺癌的危险性降低,

1 Kripp l P, LangsenlehnerU, RennerW, et al. A common 936 C /T

gene polymorphism of vascular endothelial growth factor is associated

with decreased breast cancer risk. Int J Cancer, 2003, 106: 4682

471.

我们进行了一系列的生长因子基因多态性与结

直肠癌关系的研究,已经发现VEGF 61 G/G基因型

和G等位基因与结直肠癌的发生有关[ 9 ] 。VEGF

936 T/C 基因多态性与结直肠癌关系的研究表明

VEGF 936 C /C基因型或936 C等位基因与结直肠

癌的生成无关,但有助于减少术后结肠吻合口瘘的

发生。含有VEGF 936 T基因的结直肠癌患者术后

并发吻合口瘘的机会增加,或许VEGF 936 T基因

可作为检测结直肠癌或预测结直肠癌术后并发吻合

口瘘的一个危险因素,但这需要进一步的研究。同

时观察这一基因多态性在其他伤口愈合并发症中的

作用也将很有意义。

血管内皮生长因子936 T/C基因多态性

与结直肠癌及术后吻合口瘘的关系

吴国洋王效民Michael Keese Till Hasenberg JÊrgW. Sturm

血管内皮生长因子基因多态性与肺癌危险度的关系

Lee SJ , Lee SY, Jeon HS, et al/ / Cancer Ep idemiol Biomarkers Prev, 2005, 14: 571 - 575

背景和目的:血管生成是包括肺癌在内的恶性肿瘤发

生、发展和转移中的一个重要过程。血管内皮生长因子基

因( vascular endothelial growth factor, VEGF)变异可以导致

其编码蛋白的产量和活性的改变,通过作用于肿瘤的血管

生成过程,从而引发个体对肺癌易感性的差异。为了检验

这一假设,作者研究了韩国人VEGF基因的3个单核苷酸多

态性( - 460T >C、+ 405C > G和936C > T)及其单倍型和肺

癌危险度之间的关系。方法:研究对象包括432名肺癌患者

和432名年龄和性别匹配的对照。运用贝叶斯定理构建单

体型。采用logistic回归校正相关协变量计算OR值。结果:

在+ 405位点,与CC和CG基因型比较, GG基因型个体小

细胞肺癌危险度显著降低,调整OR 值为0136, 95%可信限

为0117～0178; 936位点变异基因型(CT和CT + TT)个体较

野生基因型(CC)个体小细胞肺癌的危险度降低,调整OR

值分别为0147和0144, 95%可信限分别为0126～0185和

0124～0180。CGT单体型与小细胞肺癌的危险度降低相关,

调整OR值为0139, 95%可信限为0118～0187;而TCC与小

细胞肺癌的危险度增加相关,调整OR 值为1163, 95%可信

限为1114～2133。上述多态性对小细胞肺癌以外的肺癌类

型的危险度没有影响。单体型TCT和TGT与整体肺癌危险

度相关,调整OR值分别为0138和3194, 95%可信限分别为

0125～0160和2100～7176, TCT和TGT单体型的这种作用

在3种主要的肺癌组织类型中均有发现。结论: VEGF基因

多态性与个体肺癌遗传易感性有关。

(冷曙光)

Objectives: Vascular endothelial growth factor (VEGF) is a potent stimulus

of angiogenesis that has an important role in many human

malignancies including prostate carcinoma (PCa). We evaluated the role of the functional VEGF polymorphisms as genetic markers for

PCa susceptibility and prognosis. Methods: The study included 101 patients with PCa and the 100 age-matched healthy men. The VEGF

genotypes _1154G > A were identified by allele-specific polymerase chain reaction (AS-PCR) and the genotypes _634G > C and

936C > T were identified by restriction fragment length

polymorphism-polymerase chain reaction (RFLP-PCR). Results: A negative association was found between VEGF _1154AA genotype and PCa risk (OR = 0.27; P = 0.009). Furthermore, the presence of the

VEGF _1154A allele appeared to be associated with an increased risk of higher tumor grade (OR = 0.37; P = 0.01). A significant

increased risk of prostate cancer was associated with the VEGF _634 (GC + CC) combined genotype (OR = 1.95; P = 0.02). The VEGF

_634C allele was associated with the aggressive phenotype of prostate cancer as defined by the high histological grade (OR = 3.48;

P = 0.007). The VEGF _1154A/_634G haplotype was negatively associated with PCa risk (OR = 0.48; P = 0.005) and high tumor

grade compared to low grade (OR = 0.37; P = 0.02). Conclusions: Genetic variations in the VEGF may predict not only PCa risk

but also tumor aggressiveness.

Association of VEGF genetic polymorphisms with prostate

carcinoma risk and clinical outcome

Sana Sfar a,*, Elham Hassen a, Hamadi Saad b, Faouzi Mosbah c, Lotfi Chouchane a

a Laboratoire d’Immuno-Oncologie Mole′culaire, Faculte′ de Me′decine de Monastir, Universite′ de Monastir, Tunisia

b Service d’Urologie, Hopital Universitaire Fattouma Bourguiba, Monastir, Tunisia

c Service d’Urologie, Hopital Universitaire Sahloul, Sousse, Tunisia

Received 1 February 2006; received in revised form 7 June 2006; accepted 2 July 2006

Abbreviations used: PCa, prostate carcinoma; VEGF, vascular endothelial

growth factor; DC, dendritic cells; NF-j B, nuclear factor-j B; SNP,

single nucleotide polymorphism; PSA, prostate-specific antigen; RFLPPCR,

restriction fragment length polymorphism PCR; AS-PCR, allele

specific PCR; OR, odds ratio.

Associations of Single Nucleotide Polymorphisms in

the Vascular Endothelial Growth Factor Gene with the Characteristics and Prognosis of Renal Cell Carcinomas

Yoshihisa Kawai, Shigeru Sakano, Yoshihito Korenaga, Satoshi Eguchi, Katsusuke Naito *

Department of Urology, Yamaguchi University School of Medicine, Yamaguchi, Japan